In Conversation with Helen Sabzevari, President & CEO of Precigen A desire to end disease has taken her from a childhood in Iran to the Scripps Institute, to the NIH [….]
In Conversation with Helen Sabzevari, President & CEO of Precigen
5 Reasons You Can’t Miss This Year’s Women In Bio – Capital Region’s HERstory Gala
5 Reasons You Can’t Miss This Year’s Women In Bio – Capital Region’s HERstory Gala By Arielle Garcia | February 5, 2024 Dear BioBuzz and Women In Bio Members and [….]
Weekly Quick Hits (BioHealth Capital Region) – Week of May 29, 2023
Weekly Quick Hits (BioHealth Capital Region) – Week of May 29, 2023 By Sarah EllinwoodJune 2, 2023 Funding, Awards and Collaborations BCWorld Healthcare and ReGelTec Enter Exclusive Distribution Agreement for [….]
Weekly Quick Hits (BioHealth Capital Region) – Week of April 24, 2023
Weekly Quick Hits (BioHealth Capital Region) – Week of April 24, 2023 By Sarah Ellinwood, Alex Keown, and Mark TerryApril 28, 2023 Funding, Awards and Collaborations Quest Diagnostics Acquires Haystack [….]
Weekly Quick Hits (BioHealth Capital Region) – Week of April 17, 2023
Weekly Quick Hits (BioHealth Capital Region) – Week of April 17, 2023 By Sarah Ellinwood, Alex Keown, and Mark TerryApril 21, 2023 Funding, Awards and Collaborations OpGen Enters Into Distribution [….]
Weekly Quick Hits (BioHealth Capital Region) – Week of April 3, 2023
Weekly Quick Hits (BioHealth Capital Region) – Week of April 3, 2023 By Sarah Ellinwood, Alex Keown, and Mark TerryApril 7, 2023 Funding, Awards and Collaborations Horizon Therapeutics Named to [….]
Weekly Quick Hits (BioHealth Capital Region) – Week of March 27, 2023
Weekly Quick Hits (BioHealth Capital Region) – Week of March 27, 2023 By Sarah Ellinwood, Alex Keown, and Mark TerryMarch 31, 2023 Funding, Awards and Collaborations 10Pearls Acquires Consulting Firm [….]
Precigen’s Experimental RRP Treatment Shows Early Signs of Promise
In January, the Germantown-based company announced positive data from a Phase I dose escalation and expansion cohort for the potential first-in-class PRGN-2012 off-the-shelf (OTS) AdenoVerse. Data shared by Precigen during its R&D Day presentation showed treatment with PRGN-2012 significantly reduced the need for surgeries for severe, aggressive RRP patients who received Dose Level 2 of the medication.
Weekly Quick Hits (BioHealth Capital Region) – Week of January 23, 2023
Here’s what’s been happening the BioHealth Capital Region’s Life Science scene the week of January 23, 2023
Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients
Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented positive Phase 1 dose escalation data from the ongoing Phase 1/1b clinical study of PRGN-3006 UltraCAR-T® in patients with r/r AML and higher risk myelodysplastic syndromes (MDS) (clinical trial identifier: NCT03927261) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract# 4633). The presentation was delivered by David A. Sallman, MD, Assistant Member in the Department of Malignant Hematology at the H. Lee Moffitt Cancer Center & Research Institute (Moffitt) and a lead investigator for the PRGN-3006 clinical trial.